
    
      Hematocrit <45% in men or <42% in women at 1Â°evaluation within 6 months In case of complete
      or partial responsiveness, experimental treatment will be continued until 12 months In case
      of disease progression or treatment failure, experimental drug will be withdrawn and patient
      will be out of the study
    
  